Processing math: 100%
 

The role of TNF-α inhibitor in glioma virotherapy: A mathematical model

  • Received: 22 June 2016 Accepted: 30 June 2016 Published: 01 January 2017
  • MSC : Primary: 92C42, 92C50; Secondary: 49J15

  • Virotherapy, using herpes simplex virus, represents a promising therapy of glioma. But the innate immune response, which includes TNF-α produced by macrophages, reduces the effectiveness of the treatment. Hence treatment with TNF-α inhibitor may increase the effectiveness of the virotherapy. In the present paper we develop a mathematical model that includes continuous infusion of the virus in combination with TNF-α inhibitor. We study the efficacy of the treatment under different combinations of the two drugs for different scenarios of the burst size of newly formed virus emerging from dying infected cancer cells. The model may serve as a first step toward developing an optimal strategy for the treatment of glioma by the combination of TNF-α inhibitor and oncolytic virus injection.

    Citation: Elzbieta Ratajczyk, Urszula Ledzewicz, Maciej Leszczynski, Avner Friedman. The role of TNF-α inhibitor in glioma virotherapy: A mathematical model[J]. Mathematical Biosciences and Engineering, 2017, 14(1): 305-319. doi: 10.3934/mbe.2017020

    Related Papers:

    [1] Yan Zhang, Shujing Gao, Shihua Chen . Modelling and analysis of a stochastic nonautonomous predator-prey model with impulsive effects and nonlinear functional response. Mathematical Biosciences and Engineering, 2021, 18(2): 1485-1512. doi: 10.3934/mbe.2021077
    [2] Chunmei Zhang, Suli Liu, Jianhua Huang, Weiming Wang . Stability and Hopf bifurcation in an eco-epidemiological system with the cost of anti-predator behaviors. Mathematical Biosciences and Engineering, 2023, 20(5): 8146-8161. doi: 10.3934/mbe.2023354
    [3] Manoj Kumar Singh, Anjali., Brajesh K. Singh, Carlo Cattani . Impact of general incidence function on three-strain SEIAR model. Mathematical Biosciences and Engineering, 2023, 20(11): 19710-19731. doi: 10.3934/mbe.2023873
    [4] Wenjie Qin, Yue Xia, Yi Yang . An eco-epidemic model for assessing the application of integrated pest management strategies. Mathematical Biosciences and Engineering, 2023, 20(9): 16506-16527. doi: 10.3934/mbe.2023736
    [5] Raimund Bürger, Gerardo Chowell, Elvis Gavilán, Pep Mulet, Luis M. Villada . Numerical solution of a spatio-temporal predator-prey model with infected prey. Mathematical Biosciences and Engineering, 2019, 16(1): 438-473. doi: 10.3934/mbe.2019021
    [6] Xue Liu, Xin You Meng . Dynamics of Bacterial white spot disease spreads in Litopenaeus Vannamei with time-varying delay. Mathematical Biosciences and Engineering, 2023, 20(12): 20748-20769. doi: 10.3934/mbe.2023918
    [7] Yun Li, Hongyong Zhao, Kai Wang . Dynamics of an impulsive reaction-diffusion mosquitoes model with multiple control measures. Mathematical Biosciences and Engineering, 2023, 20(1): 775-806. doi: 10.3934/mbe.2023036
    [8] Bruno Buonomo, Rossella Della Marca, Manalebish Debalike Asfaw . Modelling human response to information in voluntary vaccination behaviour using epidemic data. Mathematical Biosciences and Engineering, 2025, 22(5): 1185-1205. doi: 10.3934/mbe.2025043
    [9] Zixiao Xiong, Xining Li, Ming Ye, Qimin Zhang . Finite-time stability and optimal control of an impulsive stochastic reaction-diffusion vegetation-water system driven by Lˊevy process with time-varying delay. Mathematical Biosciences and Engineering, 2021, 18(6): 8462-8498. doi: 10.3934/mbe.2021419
    [10] Luyao Li, Licheng Fang, Huan Liang, Tengda Wei . Observer-based event-triggered impulsive control of delayed reaction-diffusion neural networks. Mathematical Biosciences and Engineering, 2025, 22(7): 1634-1652. doi: 10.3934/mbe.2025060
  • Virotherapy, using herpes simplex virus, represents a promising therapy of glioma. But the innate immune response, which includes TNF-α produced by macrophages, reduces the effectiveness of the treatment. Hence treatment with TNF-α inhibitor may increase the effectiveness of the virotherapy. In the present paper we develop a mathematical model that includes continuous infusion of the virus in combination with TNF-α inhibitor. We study the efficacy of the treatment under different combinations of the two drugs for different scenarios of the burst size of newly formed virus emerging from dying infected cancer cells. The model may serve as a first step toward developing an optimal strategy for the treatment of glioma by the combination of TNF-α inhibitor and oncolytic virus injection.


    Recently, Whitman and Jayaprakash [1] published a study of a simple, stochastic, agent-based model of influenza infection, Infectious diseases have been and continue to be a major public-health problem [2], disrupting people's quality of life and reducing their chances of survival. The appearance of new diseases and the repetition of mutant strains have added to their massive unhelpful blow. The control of the influenza virus, a foremost international health condition poses a scientific challenge at many levels. Influenza is caused by a virus. According to [3], it is characterized by a severe cytopathogenic respiratory disease that is infectious in nature. Based on matrix protein and nucleoprotein differences, it can be subdivide into A, B and C [4].

    Humans and animals are both infected with Types A and B. The most virulent type, i.e., the Type A virus which is now known as one of the most problematic viruses to tackle [5] is further classified based on the hemagglutinin and neuraminidase proteins located on the virus's surface. Hemagglutinin H1 to H16 and neuraminidase N1 to N9 are the two groups of proteins, the combination of which classifies the influenza subtypes. Influenza A's nomenclature is determined by a mix of hemagglutinin and neuraminidase. The H1N1 virus, for example, is influenza A with both H1 and N1 proteins; its spread is usually not epidemic, and that is why it is difficult to distinguish it from a regular cold [6].

    Another way to characterize them is by the influenza A and B strains [7]. New influenza strains emerge as a result of genetic changes or drift [8]. Antigenic drift is caused by progressive changes in the virus over time. Antibodies have a difficult time recognizing new strains. Antigenic shift, on the other hand, is characterized by fast changes in the virus that result in the emergence of a completely new strain. Influenza A can go through either of the modifications, whereas Influenza B only goes through antigenic drift [9,10].

    Vaccination is incapable of protecting against the new influenza strain. The 2009 H1N1 influenza pandemic showed this. Antivirals are thus required to halt the spread of the influenza outbreak [11]. Recently, incidences of influenza virus resistance have been discovered. The H3N2 virus resistance to aminoadamantanes and the H1N1 virus resistance to oseltamivir are two examples. Resistance is lethal and has the potential to create numerous pandemics in the future [12].

    When compared to the original strain, the transmission rate of a new strain is thought to be quite low. The fact that mutation reduces viral strength is linked to this phenomenon [13]. In the instance of H1N1 influenza virus resistance to oseltamivir, however, it was discovered that these alterations do not always affect virus transmission [14,15].

    For at least the last several centuries, the influenza virus has been responsible for periodic outbreaks of acute febrile illness every 1 to 4 years. The first influenza like sickness outbreak was documented in 1173 and 1174 [16], while the first true epidemic occurred in 1694. [17]. Between 1918 and 1919, the globe was struck by the worst epidemic in recorded history, with an estimated 21 million victims [18]. As indicated by records, it was one of the most terrible events in mankind's set of experiences. Three additional pandemics occurred in the 20th century, namely the 1957 H2N2 pandemic, the 1968 H3N2 pandemic and the 2009 flu A (H1N1) infection (pH1N1) pandemic.

    In the most famous model, a flu strain was found in Mexico and later in the United States of America with a blend of various qualities not recently seen in pig or human flu infection strains [19]. The pandemic was announced in August 2010 after the involvement of different zones [20].

    Young people have the highest rates of influenza infection, while older adults have the highest fatality rates. Mortality and morbidity are particularly high for those with certain high risk medical conditions, such as extreme aging, cardiovascular disorders and metabolic diseases such as diabetes mellitus. During the 2009 pandemic, there was an elevated risk of influenza morbidity and mortality in pregnant women [21]. Furthermore, evidence from prior pandemic and seasonal influenza outbreaks suggests that the risk of influenza complications is higher in the second half of pregnancy than in the first.

    To investigate the influence of environmental conditions on influenza transmission and make the results more realistic, we first developed a stochastic mathematical influenza model. Following that, the factors required for extinction and persistence were analyzed. The threshold of the suggested stochastic influenza model has also been established. When there is tiny or large noise, it plays a critical role in the mathematical models as a backbone [22,23]. Finally, we visualized the numerical simulations using MATLAB.

    In this section, we provide our new stochastic influenza model in the form of differential equations.

    ● The total inhabitant (t) is distributed in four compartment, i.e., St, INt, IRt and Rt, which represent the susceptible and infected people with resistance, infected peoples with non-resistance and recovered people respectively.

    ● The variables and parameters of the proposed stochastic model are non-negative.

    ● We deliberate that the variability of μ and γ is subject to stochastic white noise disturbance, i.e., μμ+σ1B1(t) and γγ+σ2B2; where B1(t)andB2(t) represent the Brownian motion with the property B1(0)=0=B2(0) and the intensities σ21andσ22 are positive.

    Remark 2.1. The deterministic general epidemic study estimates that if Rr<1, a small outburst will arise, and if Rr>1, a large outbreak will occur, infecting a large chunk of the populace. The results are based on the assumption that the community is homogeneous and that individuals mingle evenly. However, if the hypothesis of an evenly mixed society is accepted, this model may not be appropriate in particular situations. When contemplating a tiny population, such as an epidemic outbreak in a daycare center or school, it appears logical to presume that the eventual number of infected will be unpredictable or random. Also, even if Rr>1 and the society is huge, if the outbreak is started by only one (or a few) early infectives, the epidemic may never take off by accident. The formulation of a related stochastic epidemic model is motivated by these two aspects. It allows parameter estimations from disease outbreak data to include standard errors, and the subject of disease extinction is better suited for stochastic models for researching epidemic diseases.

    In light of the above speculations, we established the following new stochastic influenza model;

    dS=(bdSSINαSβIRkIR+1)dt,dIN=(αSIN(μ+d)IN)dtσ1INdB1(t),dIR=(βSIRkIR+1(γ+d)IR)dtσ2IRdB2(t),dR=(μIN+γIRdR)dt+σ1INdB1(t)+σ2IRdB2(t). (2.1)
    Table 1.  Parametric description of the model.
    Symbol Description Value
    α The rate of infection by a non-resistant strain 0.15
    β The rate of infection by a resistant strain 0.10
    γ The rate at which resistant individuals are eliminated from the inhabitants 0.75
    μ Represents the pace at which non-resistant strains are evicted from the population 0.80
    b Denotes recruitment into the susceptible group 1.00
    d The death rate 0.20
    k The effect of mutation on the resistant strain 0.10

     | Show Table
    DownLoad: CSV

    Also, we have the compartment table below:

    Table 2.  Compartments and description.
    Symbol Description Value
    S Susceptible 20
    IN Infected peoples with resistance 2
    IR Infected peoples with non-resistance 2
    R Recovered peoples 1

     | Show Table
    DownLoad: CSV

    The authors of [24] developed the following deterministic model:

    dSdt=bdSαSINSIRβkIR+1,dINdt=αSIN(d+μ)IN,dIRdt=βSIRkIR+1(d+γ)IR,dRdt=μIN+γIRdR, (2.2)

    and

    d(t)=bdt (2.3)

    where t=St+INt+IRt+Rt indicates all the constant residents for bμ and 0=S0+IN0+R0+IR0. Equation (2.3) has the exact solution

    t=edt[0+bdedt] (2.4)

    Also we have 0IN0,0S0,IR00,R00INt0,St0,IRt0andRt0, so the result has a positivity property. If Rr<1 then the model (2.2) will be locally stable and unstable otherwise. Similarly for b=0 the model (2.2) will be globally asymptotically stable.

    In this article, we will establish the computational and analytical aspects of the stochastic influenza model, and we will mathematically correlate our results with the deterministic model for future forecasts by using various parametric variables. As a result, this research can help the local community become more aware of the disease's spread.

    Here, we made the following speculations:

    Rd+={ςRd:0<ςi,d>1}.

    ● Suppose a complete probability space (Ω,,{t}t0,P) with filtration {t}t0 satisfies the usual condition.

    We reflect a common four-dimensional stochastic differential equation for the existence of the solution of our model which is described by (2.1):

    dς(t)=Θ(ς(t),t)dt)+Θ(ς(t),t)dB(t)),fort=t0 (3.1)

    with the initial condition ς(t0)=ς0Rd. By defining the differential operator Ł using (3.1), we get

    Ł=t+4i=1Θi(ς,t)ςi+125i,j=1[ΘT(ς,t)ΘT(ς,t)]ij(2ςiςj). (3.2)

    If Ł acts on the function V=(RdטR+;˜R+), then

    ŁV(ς,t)=Vt(ς,t)+Vς(ς,t)Θ(ς,t)+12trace[ΘT(ς,t)Vςς(ς,t)Θ(ς,t)]. (3.3)

    In this section, our discussion will be on the solution of the stochastic influenza model (2.1).

    Theorem 4.1. There is a unique positive solution (INt,St,IRt,Rt) of the system (2.1) for t0 with (IN0,S0,IR0,R0)R4+, and the solution will be left in R4+, with a probability equal to one.

    Proof. Because (2.1) satisfies the local Lipschitz condition [25], formally for (INt,St,IRt,Rt)R4+, we do have (INt,St,IRt,Rt)R4+ a distinctive local solution on t[0,τe), where τe is the flare-up time. Next, our aim is to show τe= for the global solution of (2.1). Assume 00 is very large so that (IN0,S0,IR0,R0) lies in [10,0]. For 0, define

    τ=inf{t[0,τe):1min{(INt,St,IRt,Rt)} or max{(INt,St,IRt,Rt)}}.

    Let inf= (because typically is the empty set). Since τ is increasing for , let τ=limτ; then, we have ττe almost surely. Next, we need to confirm τ= a.s. If this assertion is incorrect, then there exist a constant T>0 and (0,1) such that P{τT}>∈. As a consequence, we have 10 such that

    P{τT}≥∈,k1fortτ. (4.1)

    We outline a C2-function U:R4+R+ by using the resulting formulation

    U(INt,St,IRt,Rt)=(Stc_~c_~lnStc_~)+(INt(34+14)lnINt)+(IRt(34+14)lnIRt)+(Rt(34+14)lnRt). (4.2)

    Obviously the function U is non-negative which can follow from z(34+14)logz0z>0. Suppose 0 and T0 are arbitrary. Applying Ito's formula to (4.2) we get

    dU(INt,St,IRt,Rt)=(11INt)dINt+12I2Nt(dINt)2+(11IRt)dIRt+12I2Rt(dIRt)2+(11Rt)dRt+12R2t(dRt)2+(1c_~St)dSt (4.3)
    =ŁU(INt,St,IRt,Rt)+σ1(INtSt)dB1(t)+σ2(IRtSt)dB2(t), (4.4)

    where ŁU:R4+R+ is defined by

    ŁU(INt,St,IRt,Rt)=(1c_~St)(bdStαStINtStβIR1+kIRt)+(11INt)(αStINt(d+μ)INt)+12σ21+(11IRt)(βStIRt1+kIRt(d+r)IRt)+12σ22+(11Rt)(μINt+γIRtdRt)+12σ21+12σ22=bdStαStINtβStIRt1+kIRtc_~bSt+c_~d+c_~αINt+c_~βIRt1+kIRt+αStINt+(d+γ)INtαSt+(d+μ)+StβIRt1+kIRt(d+γ)IRt+(d+γ)βSt1+kIRt+μINt+γIRtdRtγ+dμINtRt+σ21+σ22bdStαStINt+c_~d+c_~αINt+αStINt+(d+γ)INtαSt+(2d+μ+γ)dIRtγIRt+μINt+γIRtdRtγ+d+σ21+σ22b+c_~d+c_~αINt+αStINt+(d+γ)INt+(d+γ)+γIRt+μINt+d+σ21+σ22B. (4.5)

    Thus, we have

    ˉE[U(St(τȷ),(INt(τȷ),(IRt(τȷ),(R(τȷ)]U(S0,IN0,IR0,R0+ˉE[τȷ0Kdt]U(S0,IN0,IR0,R0)+K. (4.6)

    We consider that Ωȷ={σȷ} for all ȷȷ1 and by (2.3), P(Ωȷ)ϵ. We comment that for every ωΩȷ there exist at least St(τȷ,ω),INt(τȷ,ω),IRt(τȷ,ω)andR(τȷ,ω), equaling the value ȷ or 1ȷ then we get that U(St(τȷ),INt(τȷ),IRt(τȷ),R(τȷ)) is not less than ȷ1logȷ or (1ȷ)1+logȷ. Accordingly,

    U(St(τȷ),INt(τȷ),IRt(τȷ),R(τȷ))ˉE(ȷ1logȷ)(1ȷ)1+logȷ). (4.7)

    From (4.1) and (4.6), we get the following relation

    U(S0,IN0,IR0,R0)+KˉE[1ΩȷU(St(τȷ),INt(τȷ),IRt(τȷ),Rt(τȷ))]ξ[(ȷ1logȷ)((1ȷ)1+logȷ)], (4.8)

    where 1Ωȷ denotes the indicator function. We observe that k leads to the ambiguity >U(S0,IN0,IR0,R0)+M=, which implies that τ= a.s.

    In this part, we determine when the sickness will be cured and when it will be revived. As a result, the system's (2.1) vital reproduction is demonstrated. Based on the proof in [26], we can deduce the subsequent lemmas:

    Lemma 5.1. Let (St,INt,IRt,Rt) be the solution of the model (2.1) with the initial values given by (S0,IN0,IR0,R0)R4+, ; then, limtINt+St+IRt+Rtt=0 is almost certain.

    In fact, together with the positivity of the solution and the system (2.1), we have that limtStt=0 limtINtt=0, limtIRtt=0 and limtRtt=0 a.s.

    Lemma 6.1. Suppose d>(12σ2112σ22). Assume (St,INt,IRt,Rt) is the solution of the model (2.1) with initial values given by (S0,IN0,IR0,R0)R4+; then,

    limtt0IR(s)dB2(s)t=0,limtt0IN(s)dB1(s)t=0. (6.1)

    Let

    Rr=αbd(d+μ+12σ21)=Rrαb2d(d+μ)(d+μ+12σ21)σ21,

    where

    Rr=αbd(d+μ) (6.2)

    is the deterministic model's fundamental reproduction number.

    In this segment, we scrutinize the condition for the disappearance of the influenza model (2.1), we lead with the following representation and definition. Let ȷ(t)=1tt0ȷ(r)dr, then the following are the outcomes for the disease's termination.

    Theorem 7.1. Let (St,INt,R,IRt) be the solution of the stochastic influenza model (2.1), with the initial values given by (S0,IN0,R0,IR0)Ω. If Rr<1 then limt(logINtt)<0 and limt(logIRtt)<0; almost surely, INt0 and IRt0 exponentially a.s which means that the disease terminates with a probability of one). Also limtt0St=(bd), limtINt(t)(t)=0, limtIRt(t)=0 and limtt0Rt(t)=0.

    Proof. After integrating (2.1), we can get the following system of equations

    StS0t=bdStαStINtβStIRt1+kIRt,INtIN0t=αStINt(d+μ)INt1tσ1t0INt(r)dB1(r),IRtIR0t=βStIRt1+kIRt(d+γ)IRt1tσ2t0IRt(r)dB2(r),RtR0t=μINt+γIRtdR+1tσ1t0INt(r)dB1(r)+1tσ2t0IRt(r)dB2(r), (7.1)
    StS0t+INtIN0t+IRtIR0t+RtR0t=bdStdINtdIRtdR, (7.2)
    St=bdINtIRtRt+Φ(t), (7.3)

    where

    Φ(t)=1d[StS0t+INtIN0t+IRtIR0t+RtR0t] (7.4)

    Obviously Φ(t)0 as t. Applying Ito's formula to the second equation of (2.1) gives

    dlogINt=(αSt(d+μ)+12σ21)dtσ1dB1(t) (7.5)

    If we Integrate (7.5) from 0 to t and divide by t, we get

    logINtlogIN0t=αSt(d+μ)+12σ211tσ1t0dB1(r) (7.6)

    Substituting (7.3) in (7.6), we have

    logINtlogIN0t=α[bdINtIRtRt+Φ(t)](d+μ)+12σ211tσ1t0dB1(r)αbd(d+μ)+12σ21αINtαIRtαRt1tσ1t0dB1(r)+Φ(t)=(d+μ12σ21)(1Rr)αINtαIRtαRt+, (7.7)

    where

    =Φ(t)1tσ1t0dB1(r). (7.8)

    For =0 and t, we have

    limtsuplogINtt(d+μ12σ21)(1Rr)αINtαIRtαRt. (7.9)

    Equation (7.9) implies that

    limtINt=0. (7.10)

    Similarly, it may also be proved that

    limtIRt=0. (7.11)

    Now for St, we have the following from the first equation of the model (2.1)

    StS0t=bdt0Stdtαt0StINtdtt0βStINt1+kIRt,dt0Stdt=bαt0StINtdtt0βStINt1+kIRtStS0t,t0Stdt=bdαdt0StINtdtt0βdStINt1+kIRt1b(StS0t). (7.12)

    This implies that limtt0St=bd. Now from the fourth equation of the system (2.1), it follows that

    Rt=edt[R0+t0μIN(r)edt+t0γIR(r)edt]. (7.13)

    By applying the L'Hospital's rule to the above result, we get

    limtt0Rdt=0, (7.14)

    which completes the proof.

    In this section, we will investigate the necessary conditions for the persistence of the disease.

    Theorem 8.1. Assume d>(12σ2112σ22). Let (St,INt,IRt,Rt) be the solution of the stochastic influenza model (2.1), with the initial values given by (S0,IN0,IR0,R0)R4+. If Rr>1, then

    limtt0S(s)ds=bdRra.s,limtt0IN(s)ds=d(d+μ+12σ21)α(d+μ)(Rr1)a.s.,limtt0R(s)ds=μ(d+μ+12σ21)α(d+μ)(Rr1)a.s.,limtt0IR(s)ds=[d(d+μ+12σ21)((d+μ+12σ21)(d+γ+12σ21)αd))αdk(d+γ(bαd(d+μ+12σ21)))](Rr1)a.s.

    Proof. If Rr>1, then by (7.9) and Lemmas 5.1 and 5.2 in [27], we have

    limtt0IN(s)ds=bαd(d+μ+12σ21)α(d+μ)d=d(d+μ+12σ21)d+μ(Rr1). (8.1)
    limtt0S(s)ds=bdd+μ+12σ21α(Rr1)=bdRr.

    Now from the fourth equation of model (2.1), we obtain

    RtR0t=μtt0IN(s)ds+γtt0IR(s)dsdtt0R(s)ds+σ1tt0IN(s)dB1(s)+σ2tt0IR(s)dB1(s),1tt0R(s)ds=μtt0IN(s)ds+ð, (8.2)

    where

    ð=γtt0IR(s)dsdtt0R(s)ds+σ1tt0IN(s)dB1(s)+σ2tt0IR(s)dB1(s)RtR0t,

    ð(t) has the property that

    limtð=0. (8.3)

    By substituting (8.1) in (8.2), we have

    limtt0R(s)ds=μ(d+μ+12σ21)α(d+μ)(Rr1).

    Now from the third equation of the model (2.1), using Ito's formula yields

    d(lnIRtkIRt)=[βSt(d+γ)k(d+γ)IRt12σ22]dt+σ2dB2(s). (8.4)

    Integrating (8.4) from 0 to t, we have

    lnIRtIR0t+k(IRtIR0t)=βtt0S(s)ds(d+γ+12σ22)k(d+γ)tt0IR(s)ds+1tt0σ2dB2(s)=bβdRrk(d+γ)tt0IR(s)ds+1tt0σ2dB2(s)(d+γ)12σ22k(d+γ)tt0IR(s)ds=bβdRr+1tt0σ2dB2(s)(d+γ)12σ22[lnIRtIR0t+k(IRtIR0t)],
    1tt0IR(s)ds=1k(d+γ)[bβdRr12σ22(d+γ)+(s)], (8.5)

    where (s)=1tt0σ2dB2(s)(lnIRtIR0t+k(IRtIR0t); ð(t) has the property that

    limt(s)=0. (8.6)

    Taking the limit of (8.5) and incorporating the value Rr we have

    limtt0IR(s)ds=[d(d+μ+12σ21)((d+μ+12σ21)(d+γ+12σ21)αd))αdk(d+γ(bαd(d+μ+12σ21)))](Rr1)a.s.

    This completes the proof.

    We have accomplished our analysis of disease extinction and persistence. We will now perform some numerical simulations of (2.1) to illustrate the applicability of our findings. The Milstein technique [28] was used to generate the numerical simulations. Consider the model's discretization equation:

    Sk+1=Sk+(bdSkαSkINkβSkIRk1+kIRk)Δt,INk+1=INk+(αSkINk(d+μ)INk)Δtσ1INkΔtτkσ212INk(τ2k1)Δt,IRk+1=IRk+(βSkIRk1+kIRk(d+γ)IRk)Δtσ2IRkΔtτkσ222IRk(τ2k1)Δt,Rk+1=Rk+(μINk+γIRkdRk)Δt+σ1INkΔtτk+σ212INk(τ2k1)Δt,+σ2IRkΔtτk+σ222IRk(τ2k1)Δt.

    Here, we shall discuss the graphical description of the model (2.1). In Figure 1, we have illustrated a numerical solution of the model (2.1) and those obtained in comparative studies of all the classes for the white noise values σ1=σ2=0.0,0.05,0.10,0.12 and S(0)=20,IN(1)=2,IR(1)=2,R(1)=1, b=1.00,d=0.20,α=0.15,μ=0.80,β=0.10,γ=0.75, andk=0.10. In Figure 2, we have illustrated a numerical solution of the model (2.1) and those obtained in comparative studies of all the classes for the white noise values σ1=σ2=0.0,0.05,0.10,0.12 and S(0)=20,IN(1)=2,IR(1)=2,R(1)=1, b=1.00,d=0.20,α=0.60,μ=0.20,β=0.10,γ=0.75, andk=0.10. We have observed that there is an important role in the dynamics of the values for α and μ. As α was increased from 0.15 to 0.60 and μ was decreased from 0.80 to 0.20, we observed a rapid fall in the susceptible class and IN increased for the cases with the white noise and without white noise. In this case the recovery rate also increased. The role of white noise has presented a change in the dynamics more accurately. Figure 3 represents the joint solutions for the model (2.1) at zero noise for different values of μ and α. The left side corresponds to μ=0.80 and α=0.15 while the right side graphs show the joint solution at μ=0.15 and α=0.60. This change shows a clear difference in the dynamics.

    Figure 1.  Numerical results for the model (2.1) at σ1=σ2=0.0,0.05,0.10,0.12.
    Figure 2.  Numerical results for the model (2.1) at σ1=σ2=0.0,0.05,0.10,0.12.
    Figure 3.  Joint solution of the model (2.1) at zero noise.

    In this work, we have explored the dynamic behavior of an SINIRR influenza stochastic model that ponders the effects of information interference and environmental noise. Information interventions and white noise have been discovered to have a significant impacts on the condition. Hereafter, we present our primary findings.

    We have measured the effects of environmental white noise on the disease. We have shown that Rr is a threshold of the model (2.1) for the disease to die out or persist, and that noise strength can change the value of the stochastic reproduction number Rr. If Rr<1, the disease will die out with a probability of one. On the other hand, if Rr>1, there is a stationary distribution for the model (2.1), which means that the disease will prevail. The discretization approach was used to construct a numerical scheme for the model simulations. The results of the simulations are presented throughout the article in the form of graphs that are divided into three sections. In Figure 2, we have shown a numerical solution of the model (2.1) as well as those obtained in comparative studies of all classes for the white noise values σ1=σ2=0.0,0.05,0.10,0.12 and S(0)=20,IN(0)=2,IR(0)=2,R(0)=1, b=1.00,d=0.20,α=0.60,μ=0.20, andβ=0.10. We have seen that the dynamics of the values for α and μ play an essential role. We noticed a rapid fall in the susceptible class as the α value was increased from 0.15 to 0.60 and μ dropped from 0.80 to 0.20; additionally, IN was increased for both instances with and without white noise. The healing rate was also boosted in this instance. White noise has played a larger role in influencing the dynamics.

    The joint solutions for the model (2.1) at zero noise are shown in figure 3 for different values of μ and α. The left side graphs correspond to μ=0.80 and α=0.15, whereas the right side graphs correspond to μ=0.15 and α=0.60 for the combined solution. This shift reveals a significant shift in the dynamics.

    J. Alzabut is thankful to Prince Sultan University and OSTİM Technical University for their endless support. G. Alobaidi was supported by Faculty research grant from the American University of Sharjah (Project number FRG21-S-S05).

    The authors declare there is no conflict of interest.

    [1] [ C. Antoni,J. Braun, Side effects of anti-TNF therapy: Current knowledge, Clin Exp Rheumatol, 22 (2002): 152-157.
    [2] [ B. Auffinger,A.U. Ahmed,M.S. Lesniak, Oncolytic virotherapy for malignant glioma: Translating laboratory insights into clinical practice, Front. Oncol., 3 (2013): 1-32.
    [3] [ E.A. Chiocca, Oncolytic viruses, Nat. Rev. Cancer, 2 (2002): 938-950.
    [4] [ L.K. Csatary,G. Gosztonyi,J. Szeberenyi,Z. Fabian,V. Liszka,B. Bodey,C.M. Csatary, MTH-68/H oncolytic viral treatment in human highgrade gliomas, J. Neurooncol, 67 (2004): 83-93.
    [5] [ A. Friedman,J. Tian,G. Fulci,E. Chioca,J. Wang, Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity, Cancer Res., 66 (2006): 2314-2319.
    [6] [ G. Fulci,L. Breymann,D. Gianni,K. Kurozomi,S.S. Rhee,J. Yu,B. Kaur,D.N. Louis,R. Weissleder,M.A. Caligiuri,E.A. Chiocca, Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses, PNAS, 103 (2006): 12873-12878.
    [7] [ I. Ganly,D. Kirn,G. Eckhardt,G.I. Rodriguez,D.S. Soutar,R. Otto,A.G. Robertson,O. Park,M.L. Gulley,C. Heise,D.D. Von Hoff,S.B. Kaye,S.G. Eckhardt, A phase I study of ONYX-015, an EiBattenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, Clin. Cancer Res., 6 (2000): 798-806.
    [8] [ M.P. Hallsworth,C.P. Soh,S.J. Lane,J.P. Arm,T.H. Lee, Selective enhancement of GM-CSF, TNF-alpha, IL-1 and IL-8 production by monocytes and macrophages of asthmatic subjects, Eur Respir J., 7 (1994): 1096-1102.
    [9] [ W. Hao,E.D. Crouser,A. Friedman, Mathematical model of sarcoidosis, PNAS, 111 (2014): 16065-16070.
    [10] [ K. Jacobsen,L. Russel,B. Kaur,A. Friedman, Effects of CCN1 and macrophage content on glioma virotherapy: A mathematical model, Bull Math Biol, 77 (2015): 984-1012.
    [11] [ F.R. Khuri,J. Nemunaitis,I. Ganly,J. Arseneau,I.F. Tannock,L. Romel,M. Gore,J. Ironside,R.H. MacDougall,C. Heise,B. Randley,A.M. Gillenwater,P. Bruse,S.B. Kaye,W.K. Hong,D.H. Kirn, A controlled trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat. Med., 6 (2000): 879-885.
    [12] [ Y. Kim, H. G. Lee, N. Dmitrieva, J. Kim, B. Kaur and A. Friedman, Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: A mathematical model PLOS ONE 9 (2014), e102499.
    [13] [ R.M. Lorence,A.L. Pecora,P.P. Major,S.J. Hotte,S.A. Laurie,M.S. Roberts,W.S. Groene,M.K. Bamat, Overview of phase I studies of intravenous administration of PV701, an oncolytic virus, Curr. Opin. Mol. Ther., 5 (2003): 618-624.
    [14] [ J.M. Markert, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, Gene. Ther., 7 (2000): 867-874.
    [15] [ W.H. Meisen,E.S. Wohleb,A.C. Jaime-Ramirez,C. Bolyard,J.Y. Yoo,L. Russel,J. Hardcastle,S. Dubin,K. Muili,J. Yu,M. Callgiuri,J. Godbout,B. Kaur, The impact of macrophage-and microglia-secreted TNF-α on oncolitic hsv-1 therapy in the glioblastoma tumor microenvironment, Clin Cancer Res., 21 (2015): 3274-3285.
    [16] [ T. Mineta,S. Rabkin,T. Yazaki,W. Hunter,R. Martuza, Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas, Nat. Med., 1 (1995): 938-943.
    [17] [ J.C. Oliver,L.A. Bland,C.W. Oettinger,M.J. Arduino,S.K. McAllister,S.M. Aguero,M.S. Favero, Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge, Lymphokine Cytokine Res., 12 (1993): 115-120.
    [18] [ R. Rodriguez,E.R. Schuur,H.Y. Lim,G.A. Henderson,J.W. Simons,D.R. Henderson, Prostate attenuated replication competent daenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific anti-positive prostate cancer cells, Cancer Res., 57 (2000): 2559-2563.
    [19] [ H. Schättler and U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies Springer Publishing Co., New York, USA, 2015.
    [20] [ G. Wollmann,K. Ozduman,A. N. van den Pol, Oncolytic virus therapy for glioblastoma multiforme: Concepts and candidates, Cancer J., 18 (2012): 69-81.
    [21] [ J.T. Wu,H.M. Byrne,D.H. Kirn,L.M. Wein, Modeling and analysis of a virus that replicates selectively in tumor cells, Bull. Math. Biol., 63 (2001): 731-768.
    [22] [ J.T. Wu,D.H. Kirn,L.M. Wein, Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response, Bull. Math. Biol., 66 (2004): 605-625.
  • This article has been cited by:

    1. Wenxuan Li, Suli Liu, Dynamic analysis of a stochastic epidemic model incorporating the double epidemic hypothesis and Crowley-Martin incidence term, 2023, 31, 2688-1594, 6134, 10.3934/era.2023312
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(4535) PDF downloads(589) Cited by(13)

Figures and Tables

Figures(10)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog